Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
alnylam pharmaceuticals
boston blog main
5
×
clinical trials
life sciences
national blog main
rna interference
5
×
boston
boston top stories
drugs
fda
new york blog main
new york top stories
patisiran
akcea therapeutics
aminolevulinic acid
biotech
givosiran
hereditary transthyretin amyloidosis
inotersen
national top stories
onpattro
regeneron pharmaceuticals
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
tafamidis
vyndaqel
accelerated approval
acute hepatic porphyria
acute hepatic porphyrias
akin akinc
alirocumab
amgen
andrew fire
barry greene
boston university
craig mello
dan ollendorf
evercore isi
What
alnylam
5
×
drug
medicine
pharmaceuticals
rna
fda
rnai
ago
data
interference
new
ok
second
seek
speedy
afternoon
alnylam’s
approval
approve
approved
awaits
based
biological
cholesterol
cleared
crossed
decades
decision
discovered
evidence
far
fingers
friday
gets
heart
historic
history
indicated
landmark
lasting
Language
Current search:
alnylam
×
" rna interference "
×
" boston blog main "
×
@xconomy.com
5 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision